+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Emcure Pharmaceuticals Ltd - Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Emcure Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - A summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Emcure Pharmaceuticals Ltd (Emcure) develops, manufactures, and commercializes pharmaceutical products worldwide. The company develops and manufactures branded generic products. It also manufactures active pharmaceutical ingredients (APIs) primarily for use in the manufacturing of pharmaceutical products. Emcure has a presence in all major therapeutic areas, which comprises cardiology, pain and analgesics, HIV, gynecology, blood-related, anti-infective, nephrology, diabetes, and cancer among others as well as vitamins, minerals, and nutrients products. It has an operational presence in Brazil, Dubai, South Africa, Singapore, and Nigeria. The company has branch offices in Russia and Morocco. Emcure is headquartered in Pune, Maharashtra, India.

Emcure Pharmaceuticals Ltd Key Recent Developments

  • Mar 17,2022: 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with a detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Emcure Pharmaceuticals Ltd - Key Facts
  • Emcure Pharmaceuticals Ltd - Key Employees
  • Emcure Pharmaceuticals Ltd - Key Employee Biographies
  • Emcure Pharmaceuticals Ltd - Major Products and Services
  • Emcure Pharmaceuticals Ltd - History
  • Emcure Pharmaceuticals Ltd - Company Statement
  • Emcure Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Emcure Pharmaceuticals Ltd - Business Description
  • R&D Overview
  • Emcure Pharmaceuticals Ltd - Corporate Strategy
  • Emcure Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Emcure Pharmaceuticals Ltd - Strengths
  • Emcure Pharmaceuticals Ltd - Weaknesses
  • Emcure Pharmaceuticals Ltd - Opportunities
  • Emcure Pharmaceuticals Ltd - Threats
  • Emcure Pharmaceuticals Ltd - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Emcure Pharmaceuticals Ltd, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Mar 17, 2022: 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries
Section 5 - Appendix
  • Methodology
  • Contact Us
  • Disclaimer
List of Tables
  • Emcure Pharmaceuticals Ltd, Key Facts
  • Emcure Pharmaceuticals Ltd, Key Employees
  • Emcure Pharmaceuticals Ltd, Key Employee Biographies
  • Emcure Pharmaceuticals Ltd, Major Products and Services
  • Emcure Pharmaceuticals Ltd, History
  • Emcure Pharmaceuticals Ltd, Other Locations
  • Emcure Pharmaceuticals Ltd, Subsidiaries
  • Emcure Pharmaceuticals Ltd, Key Competitors
  • Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Emcure Pharmaceuticals Ltd, Recent Deals Summary
List of Figures
  • Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Emcure Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Societal CDMO Inc
  • Labcorp Drug Development
  • Endo International Plc
  • Alcami Corp
  • Charles River Laboratories International Inc